Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 11 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
Sudden Cardiac Death Risk in Newly Diagnosed Heart Failure: SCD-PROTECT
Author(s): Marat Fudim , David Duncker Added: 4 weeks ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19… View more

Electrophysiology & Arrhythmia

Heart Failure
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 3 months ago

Guidelines & Statements
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 5 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
ACC 2025: Lifetime Benefit by Control of Modifiable Risk Factors
Author(s): Christina Magnussen Added: 11 months ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global… View more

Cardiovascular Renal Metabolic
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Joshua Stolker , Philippe Gabriel Steg , Roberta Rossini , et al Added: 10 months ago

COVID-19

MI/ACS
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s): Naveed Sattar , Philippe Gabriel Steg , Lale Tokgözoğlu , et al Added: 1 year ago
Watch this on-demand programme chaired by Prof Naveed Sattar (School of Cardiovascular and Metabolic Health, Glasgow, UK). Radcliffe Cardiology presents a distinguished panel of experts: Prof Gabriel Steg (University Institute of France, Paris, FR), Prof Lale Tokgozoglu (Hacettepe University, Ankara, TR), and Dr Joshua Stolker (St Louis Hospital, Missouri, US). This roundtable discussion explores… View more

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 2 years ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic